Filing Flows › Vericel (VCEL) › R&D spending
Vericel (VCEL) R&D spending by quarter
Vericel's R&D spending was $6.9M in Q3 2026 (third quarter 2026), -8% from Q2 2026. Over the last 7 quarters it ranged from $6.3M (Q3 2025) to $8.1M (Q1 2026).
| Quarter | R&D spending | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $6.9M | -8% | +9% |
| Q2 2026 | $7.5M | -8% | +11% |
| Q1 2026 | $8.1M | +12% | +12% |
| Q4 2025 | $7.3M | +15% | — |
| Q3 2025 | $6.3M | -6% | — |
| Q2 2025 | $6.7M | -7% | — |
| Q1 2025 | $7.3M | — | — |
Q3 2026 at a glance
Vericel, Q3 2026: revenue $85.4M (+26% year over year), operating margin 14.3%, net earnings $14.2M, operating cash flow $17.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is Vericel's R&D spending?
Vericel's R&D spending was $6.9M in Q3 2026 (third quarter 2026), -8% from Q2 2026.
How has Vericel's R&D spending changed?
Over the last 7 quarters it ranged from $6.3M (Q3 2025) to $8.1M (Q1 2026).